Deans' stroke musings: Alzheimer’s Type Neurodegeneration. Possible Correction of Memory Impairment with Intravenous Administration of Exosomes

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, December 18, 2021

Alzheimer’s Type Neurodegeneration. Possible Correction of Memory Impairment with Intravenous Administration of Exosomes

Now to get your doctors and hospital to do their jobs. Solve stroke. They need to get human testing going on this.

Alzheimer’s Type Neurodegeneration. Possible Correction of Memory Impairment with Intravenous Administration of Exosomes

Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology volume 15, pages 306–318 (2021)Cite this article

Metrics details

Abstract

Alzheimer’s disease (AD) remains one of the socially significant pathologies still lacking effective therapy. The purpose of this work was to analyze the efficacy of the intravenous (i.v.) administration of exosomes obtained from human umbilical cord Wharton jelly multipotent mesenchymal stromal cell culture supernatant. Exosomes were isolated by column filtration and characterized by the expression of specific markers and in vitro binding to mouse fibroblast cells L929. Using a model of the sporadic form of AD, it was shown that i.v. administration of exosomes prevented the deterioration of spatial memory in olfactory bulbectomized mice (OBE). The therapeutic effect was possibly due to the ability of exosomes to penetrate the brain–blood barrier of OBE animals, which was confirmed by visualization of fluorescently labeled exosomes in the cortex and hippocampus after i.v. administration of exosomes.

This is a preview of subscription content, access via your institution.